MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aradigm Company Profile (NASDAQ:ARDM)

Consensus Ratings for Aradigm (NASDAQ:ARDM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Aradigm (NASDAQ:ARDM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Aradigm (NASDAQ:ARDM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q1($0.59)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.55)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q3($0.19)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.08)($0.08)$11.60 million$10.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.06)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.07)($0.06)$6.70 million$8.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.10)($0.06)$4.80 million$6.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.09)($0.09)$4.25 million$12.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2013Q3 13($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Aradigm (NASDAQ:ARDM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Aradigm (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aradigm (NASDAQ:ARDM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Juergen Kurt FroehlichInsiderSell333$4.45$1,481.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Virgil ThompsonDirectorSell3,340$0.17$567.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013First Eagle Investment ManagemMajor ShareholderBuy40,322,580$0.12$4,838,709.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2012First Eagle Investment ManagemMajor ShareholderBuy41,666,667$0.12$5,000,000.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Aradigm (NASDAQ:ARDM)
DateHeadline
06/10/16 04:02 PMARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 11:15 AMAradigm Corp. :ARDM-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/11/16 06:22 AMTwo Presentations on Aradigm's Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference - [at noodls] - HAYWARD, Calif.--(BUSINESS WIRE)-- The first presentation is co-authored by an international team of investigators and employees of Aradigm Corporation (NASDAQ:ARDM) (the 'Company'); it discusses the details ...
05/11/16 06:00 AMTwo Presentations on Aradigm’s Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference - [Business Wire] - The first presentation is co-authored by an international team of investigators and employees of Aradigm Corporation ; it discusses the details of the design of the ongoing Phase 3 clinical trials ORBIT-3 and ORBIT-4 investigating the safety and efficacy of the Company’s investigational drug product Pulmaquin® in non-cystic fibrosis bronchiectasis patients chronically colonized with Pseudomonas aeruginosa ...
05/10/16 08:03 AMAradigm reports 1Q loss -
05/10/16 06:08 AMAradigm Announces First Quarter 2016 Financial Results - [at noodls] - HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the 'Company')today announced financial results for the first quarter and three months ended March 31, 2016. ... This is an abstract ...
04/29/16 08:42 AMActivist Starboard Value Gets Seats on Marvell Technology Group Ltd. (MRVL)’s Board; Two Other Hedge Funds Disclose Latest Moves -
04/28/16 03:08 PMARADIGM CORP Files SEC form 8-K/A, Financial Statements and Exhibits -
04/27/16 03:30 PMARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio -
04/26/16 06:26 AMAradigm Corporation Announces First Closing of Private Placement Offering of $23 Million Senior Convertible Notes Due 2021 - [at noodls] - HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ('Aradigm' or the 'Company') announced today the first closing of its previously announced private placement of $23,000,000 aggregate ...
04/25/16 11:08 AMARADIGM CORP Files SEC form 8-K, Financial Statements and Exhibits -
04/23/16 05:45 AMSlew of results disappointments hamstring S&P - Further down the food chain, Aradigm Corporation (NASDAQ:ARDM) swam against the tide, rising 155 to $4.97 as the pharmaceutical company placed $23mln of senior convertible notes due 2021. Sector peer Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was also on ...
04/22/16 07:36 AMAradigm Corporation Prices Private Placement of Senior Notes - [at noodls] - HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ('Aradigm' or the 'Company') announced today the pricing of $23 million of its senior convertible notes due 2021 and related warrants ...
03/30/16 01:33 PMARADIGM CORP Files SEC form 10-K, Annual Report -
03/17/16 06:00 AM7:00 am Aradigm announces that the EMA has approved its request to review Pulmaquin under the Centralised Authorisation Procedure drug review process -
03/17/16 06:00 AMAradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency - [Business Wire] - Aradigm Corporation today announced that the European Medicines Agency has approved its request to review Pulmaquin®, Aradigm’s investigational inhaled liposomal ciprofloxacin product, under the Centralised Authorisation Procedure drug review process.
03/15/16 06:13 AMAradigm reports 4Q loss -
03/15/16 06:00 AMAradigm Announces Fourth Quarter 2015 and Full Year Financial Results -
02/02/16 06:00 AMAradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8 - [Business Wire] - Aradigm Corporation today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 18th Annual BIO CEO & Investor Conference 2016 on Monday, February 8, 2016, at 10:30 a.m.
01/05/16 06:28 AMAradigm to Host Corporate Update Conference Call on January 6 - [at noodls] - --(BUSINESS WIRE)-- (Nasdaq:ARDM) (the 'Company') will host a corporate update conference call at () on . The Company will review recent progress with the Pulmaquin® investigational inhaled antibiotic ...
12/23/15 04:16 PMAradigm Corp.: Sudden move in price, will it continue? -
12/21/15 11:11 AMAradigm Corp. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMARADIGM CORP Financials -
12/03/15 07:40 AMHow it All Plays Out - Research on Aradigm, Ideal Power, CareDx, and Colony Bankcorp - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Aradigm Corp ...
11/12/15 02:20 PMARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
11/12/15 05:12 AMARADIGM CORP Files SEC form 10-Q, Quarterly Report -
11/11/15 06:16 AMAradigm Announces Third Quarter 2015 Financial Results - [at noodls] - HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the 'Company')today announced financial results for the third quarter and nine months ended September 30, 2015. ... This is an abstract ...
11/11/15 06:06 AMAradigm reports 3Q loss -
10/30/15 02:19 PMAradigm Corp. – Value Analysis (NASDAQ:ARDM) : October 30, 2015 -
10/13/15 06:00 AMAradigm Corporation Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3) - [Business Wire] - Aradigm Corporation today announced the completion of enrollment in the ORBIT-3 trial, the second of the two fully enrolled Phase III pivotal clinical trials of Pulmaquin®, Aradigm’s proprietary investigational formulation of inhaled ciprofloxacin, for the treatment of patients with non-cystic fibrosis bronchiectasis who have chronic lung infections with Pseudomonas aeruginosa.
09/23/15 06:25 AMAradigm to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29 - [at noodls] - HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ('Aradigm' or the 'Company') today announced that Chief Financial Officer, Nancy Pecota, will present at the Ladenburg Thalmann 2015 ...
About Aradigm

Aradigm logoAradigm Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin, which is in Phase III clinical trials. The Company also invested on AERx pulmonary drug delivery platform and other technologies. The Company's partnered programs under development include Inhaled Ciprofloxacin. The Company is also developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine) program. Its lead development candidates are the Company's formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARDM
  • CUSIP:
Key Metrics:
  • Previous Close: $4.34
  • 50 Day Moving Average: $4.44
  • 200 Day Moving Average: $3.97
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $64.65M
  • Current Quarter EPS Consensus Estimate: $-1.94 EPS
Additional Links:
Aradigm (NASDAQ:ARDM) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha